- Home
- ORGN vs CTNM Comparison
ORGN vs CTNM Comparison
Compare ORGN & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGN
- CTNM
- Stock Information
- Founded
- ORGN 2008
- CTNM 2009
- Country
- ORGN United States
- CTNM United States
- Employees
- ORGN N/A
- CTNM N/A
- Industry
- ORGN Major Chemicals
- CTNM
- Sector
- ORGN Industrials
- CTNM
- Exchange
- ORGN Nasdaq
- CTNM Nasdaq
- Market Cap
- ORGN 96.4M
- CTNM 114.1M
- IPO Year
- ORGN N/A
- CTNM 2024
- Fundamental
- Price
- ORGN $0.67
- CTNM $3.87
- Analyst Decision
- ORGN Strong Buy
- CTNM Strong Buy
- Analyst Count
- ORGN 1
- CTNM 4
- Target Price
- ORGN $3.00
- CTNM $23.75
- AVG Volume (30 Days)
- ORGN 720.1K
- CTNM 86.8K
- Earning Date
- ORGN 05-15-2025
- CTNM 05-16-2025
- Dividend Yield
- ORGN N/A
- CTNM N/A
- EPS Growth
- ORGN N/A
- CTNM N/A
- EPS
- ORGN N/A
- CTNM N/A
- Revenue
- ORGN $31,282,000.00
- CTNM N/A
- Revenue This Year
- ORGN $49.18
- CTNM N/A
- Revenue Next Year
- ORGN $144.81
- CTNM N/A
- P/E Ratio
- ORGN N/A
- CTNM N/A
- Revenue Growth
- ORGN 8.60
- CTNM N/A
- 52 Week Low
- ORGN $0.42
- CTNM $3.69
- 52 Week High
- ORGN $1.90
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- ORGN 47.17
- CTNM N/A
- Support Level
- ORGN $0.64
- CTNM N/A
- Resistance Level
- ORGN $0.71
- CTNM N/A
- Average True Range (ATR)
- ORGN 0.06
- CTNM 0.00
- MACD
- ORGN 0.00
- CTNM 0.00
- Stochastic Oscillator
- ORGN 16.65
- CTNM 0.00
About ORGN Origin Materials Inc.
Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others by using materials like food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments, and fuels.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.